Ardelyx and the LPGA Announce Multi-Year Partnership to Break Stigma Around Digestive Health Issues Impacting Millions
MWN-AI** Summary
On February 24, 2026, the Ladies Professional Golf Association (LPGA) and biopharmaceutical firm Ardelyx (Nasdaq: ARDX) announced a groundbreaking multi-year partnership aimed at breaking the stigma surrounding digestive health issues, particularly those affecting women. This initiative arises from the recognition that women constitute over 90% of individuals suffering from conditions such as irritable bowel syndrome with constipation (IBS-C), yet many remain silent due to societal taboos and lack of awareness.
Eric Foster, Ardelyx's Chief Commercial Officer, emphasized the partnership's focus on empowering women to engage in proactive health conversations with their healthcare providers. By leveraging the LPGA’s extensive platform, both organizations aim to foster open dialogue about IBS-C, which significantly impacts daily functioning, influencing mental health, relationships, and productivity.
As part of this unique alliance, Ardelyx will activate various initiatives during the LPGA Tour, merging health education with engaging golf experiences. Planned activations include digital content, onsite experiences, and participation from player ambassadors, all designed to encourage women to prioritize their health.
Monica Fee, the LPGA Chief Sales and Partnerships Officer, echoed the commitment to inspiring women on and off the golf course, stating their shared goal of advocating for informed health decisions among women. This collaboration represents a vital step towards redefining societal attitudes toward digestive health and encouraging patients to share their experiences and seek support.
Ardelyx actively develops innovative treatments for unmet medical needs, including the recently approved IBSRELA® (tenapanor) and their ongoing clinical trials for chronic idiopathic constipation. This partnership not only reflects a strategic branding opportunity for Ardelyx but also underscores a commitment to improving patient lives through empowerment and education.
MWN-AI** Analysis
The recent partnership between Ardelyx and the Ladies Professional Golf Association (LPGA) marks a strategic alliance with significant implications for both organizations, particularly regarding engagement with women's health issues, specifically digestive health. Ardelyx, known for its innovative treatments such as IBSRELA® for irritable bowel syndrome with constipation (IBS-C), stands to leverage the LPGA's extensive audience to promote awareness and education around digestive health—a sector often shrouded in stigma.
From an investment perspective, Ardelyx (Nasdaq: ARDX) could experience a favorable uptick in brand visibility and patient engagement through this partnership. The LPGA's platform will enable Ardelyx to connect directly with its target demographic, which may ultimately drive increased awareness of its product offerings and boost market demand. The strategic focus on patient empowerment aligns well with current healthcare trends favoring proactive health management, particularly among women, who represent more than 90% of IBS-C patients.
Moreover, the commitment to educational initiatives surrounding digestive conditions reflects an understanding of contemporary healthcare challenges, which aligns with Ardelyx's mission to address unmet medical needs. As the company engages in ongoing clinical trials, such as the Phase 3 ACCEL trial for chronic idiopathic constipation, successful outcomes may lead to expanded product lines and market opportunities.
Investors should, however, keep an eye on the broader market dynamics and competitive landscape. Regulatory hurdles and product development risks remain prevalent in the biopharmaceutical sector, which can affect stock volatility. Ardelyx's commitment to innovation and its thoughtful partnership strategy present a proactive approach to these challenges, making it a compelling consideration for investors interested in the intersection of healthcare and women's health initiatives. Overall, this alliance should be viewed as a promising indicator of Ardelyx's potential for growth in a crucial market segment.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
DAYTONA BEACH, Fla. and WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- The Ladies Professional Golf Association (LPGA) and Ardelyx (Nasdaq: ARDX), a biopharmaceutical company with a vision of creating a healthier tomorrow for patients, today announced a multi-year partnership naming Ardelyx as an official corporate pharmaceutical Marketing Partner of the LPGA Tour. The exclusive partnership unites two organizations dedicated to empowering women to take control of their health.
"This partnership represents a natural alignment between Ardelyx's mission and the LPGA's platform to support the digestive health of women, who account for more than 90 percent of those living with conditions like irritable bowel syndrome with constipation, yet many suffer in silence due to stigma and lack of awareness," said Eric Foster, chief commercial officer of Ardelyx. "By partnering with the LPGA, we will engage with our shared audience, not just as golf fans, but as individuals who deserve open conversations about their health. At the heart of this first-of-its-kind partnership is the ambition to educate and mobilize patients to be proactive in their health, talk to their doctor and imagine a healthier tomorrow. The LPGA's commitment to empowering women on and off the course makes them the ideal partner to help us amplify patient voices and break down barriers to care."
Together, Ardelyx and the LPGA will champion a movement that redefines how people talk about irritable bowel syndrome with constipation (IBS-C). IBS-C significantly impacts patients' daily lives, affecting mental health, relationships, work productivity and independence. However, societal taboos around digestive health often prevent open dialogue, leaving patients feeling isolated. As part of the partnership, Ardelyx and the LPGA will educate, encourage and connect patients experiencing symptoms of IBS-C and remind them that they are not alone in their journey. Through original digital and social content distributed across LPGA platforms, the collaboration aims to help patients make informed, confident and proactive decisions about their health. These values resonate with the LPGA’s mission to inspire, transform, and advance opportunities for women in golf.
"As we welcome Ardelyx as our official pharmaceutical partner, we look forward to strengthening our existing commitment to supporting healthy lifestyles," said Monica Fee, LPGA Chief Sales and Partnerships Officer. "Together, through Ardelyx's dedication to improving the lives of patients and the LPGA's diverse audience, we will advocate for women to be informed and in control of their health."
As an Official Marketing Partner, Ardelyx will activate across key LPGA moments, creating a powerful platform for impact. The 360-degree approach will include onsite experiences, custom storytelling, premium hospitality, player ambassadors and digital and social engagement to connect with women ready to take the next step in their health journey. Additional details on these partnership activations and initiatives will be announced throughout the 2026 LPGA season.
About the LPGA
The Ladies Professional Golf Association (LPGA) is the world’s premier women’s professional golf organization. Created in 1950 by 13 pioneering female Founders, the LPGA, whose Members now represent nearly 40 countries, is the longest- standing professional women’s sports organization. Through the LPGA Tour, the Epson Tour, the LPGA Professionals, and a joint venture with the Ladies European Tour, the LPGA provides female professionals the opportunity to pursue their dreams in the game of golf at the highest level. In addition to its professional tours and teaching accreditation programs, the LPGA features a fully integrated Foundation, which provides best-in-class programming for female golfers through its junior golf programming, and its LPGA Amateurs division, which offers its members playing and learning opportunities around the world. The LPGA aims to use its unique platform to inspire, transform and advance opportunities for girls and women, on and off the golf course.
Follow the LPGA online at www.LPGA.com?and download its mobile apps on Apple or Google Play. Join the social conversation on Facebook, X (formerly known as Twitter), Instagram?and YouTube.
About Ardelyx
Ardelyx is focused on the development and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). The company is also conducting a Phase 3 clinical trial, ACCEL, to assess the safety and efficacy of tenapanor for the treatment of chronic idiopathic constipation in adults and developing RDX10531, a next-generation NHE3 inhibitor with potential application across multiple therapeutic areas. Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.
Forward Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Ardelyx, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor of the Private Securities Reform Act of 1995, including the expected goals, outcomes and benefits of the LPGA partnership, such as the successful education and empowerment of patients; and the expected content and timing of partnership activations and initiatives. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control, that could cause actual outcomes or results to differ materially from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, uncertainties associated with the development of, regulatory process for, and commercialization of drugs in the U.S. and internationally. Ardelyx undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ardelyx's business in general, please refer to Ardelyx's Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 19, 2026, and its future current and periodic reports to be filed with the Securities and Exchange Commission.
LPGA Media Contact:
Annika Mayers, LPGA Communications
Annika.Mayers@lpga.com
Ardelyx Investor and Media Contact:
Caitlin Lowie, Ardelyx Investor Relations and Corporate Communications
clowie@ardelyx.com
FAQ**
How does Ardelyx Inc. ARDX plan to leverage its partnership with the LPGA to raise awareness about digestive health issues specifically impacting women in Daytona Beach, Fla., and Waltham, Mass.?
What specific initiatives will Ardelyx Inc. ARDX undertake during LPGA events to engage the communities of Daytona Beach, Fla., and Waltham, Mass., in conversations about irritable bowel syndrome and women's health?
In what ways could the collaboration between the LPGA and Ardelyx Inc. ARDX influence healthcare conversations and awareness levels in Daytona Beach, Fla., and Waltham, Mass.?
How will Ardelyx Inc. ARDX measure the impact of its partnership with the LPGA in empowering women in both Daytona Beach, Fla., and Waltham, Mass., to take control of their digestive health?
**MWN-AI FAQ is based on asking OpenAI questions about Ardelyx Inc. (NASDAQ: ARDX).
NASDAQ: ARDX
ARDX Trading
-1.97% G/L:
$6.3083 Last:
1,629,576 Volume:
$6.7158 Open:
